Company profile
Obsidian Therapeutics, Inc.
NASDAQ:OBXBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06060613 | phase1_2 | recruiting | 2023-10-25 | 2029-06-30 | Obsidian Therapeutics, Inc. | Safety and Efficacy of OBX-115 in Advanced Solid Tumors |
FDA applications (0)
No records yet.